{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:38:27Z","timestamp":1770338307344,"version":"3.49.0"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"36","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,7,22]]},"DOI":"10.18632\/oncotarget.10773","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T07:55:13Z","timestamp":1469174113000},"page":"57932-57942","source":"Crossref","is-referenced-by-count":20,"title":["Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Pengfei","family":"Jiang","sequence":"first","affiliation":[{"name":"Moores Cancer Center, UC San Diego, La Jolla, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xuzhou Central Hospital, The Affiliated XuZhou Hospital of Medical College of Southeast University, Xuzhou Clinical School of Xuzhou Medical College, Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, Jiangsu Province 221009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Mukthavaram","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, UC San Diego, La Jolla, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Nomura","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, UC San Diego, La Jolla, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep C.","family":"Pingle","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, UC San Diego, La Jolla, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayu","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, UC San Diego, La Jolla, CA 92093, USA"},{"name":"Institute of Engineering in Medicine, UC San Diego, La Jolla, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Chien","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, UC San Diego, La Jolla, CA 92093, USA"},{"name":"Institute of Engineering in Medicine, UC San Diego, La Jolla, CA 92093, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Guo","sequence":"additional","affiliation":[{"name":"Key Laboratory of Systems Biology, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201210, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[{"name":"Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute and Pacific Neuroscience Institute at Providence Saint John's Health Center, Santa Monica, CA 90404, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,22]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Rea","year":"2011","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/sj.pcan.4500607","article-title":"The potential role of bisphosphonates in prostate cancer","volume":"5","author":"Colston","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1038\/bjc.2013.270","article-title":"Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study","volume":"108","author":"San Jose","year":"2013","journal-title":"Br J Cancer"},{"key":"4","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/JTO.0b013e3181b68e5a","article-title":"Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel","volume":"4","author":"Tredaniel","year":"2009","journal-title":"J Thorac Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminoncol.2003.08.017","article-title":"Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors","volume":"30","author":"Hohneker","year":"2003","journal-title":"Semin Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Jaeggi","year":"1994","journal-title":"J Bone Miner Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1021\/jm020819i","article-title":"Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)","volume":"45","author":"Schmid","year":"2002","journal-title":"J Med Chem"},{"key":"8","unstructured":"http:\/\/www.us.zometa.com\/index.jsp?usertrack.filter_applied=true&NovaId=4029462103693076087."},{"key":"9","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S1040-8428(11)70006-3","article-title":"Anticancer evidence for zoledronic acid across the cancer continuum","volume":"77","author":"Lipton","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":"Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients","volume":"13","author":"Tonini","year":"2007","journal-title":"Clin Cancer Res"},{"key":"11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/039463201102400116","article-title":"Zoledronic acid enhances Vdelta2 T-lymphocyte antitumor response to human glioma cell lines","volume":"24","author":"Agrati","year":"2011","journal-title":"Int J Immunopathol Pharmacol"},{"key":"12","first-page":"214","article-title":"Anti-tumour activity of bisphosphonates in preclinical models of breast cancer","volume":"12","author":"Coleman","year":"2011","journal-title":"Breast Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Rogers","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2407-6-60","article-title":"Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells","volume":"6","author":"Seronie-Vivien","year":"2006","journal-title":"BMC Cancer"},{"key":"15","first-page":"4058","article-title":"Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity","volume":"109","author":"Oldfield","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Oppermann","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"17","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1073\/pnas.0702254104","article-title":"Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases","volume":"104","author":"Oldfield","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1021\/ja808285e","article-title":"Lipophilic bisphosphonates as dual farnesyl\/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation","volume":"131","author":"Leon","year":"2009","journal-title":"J Am Chem Soc"},{"key":"19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Kesari","year":"2008","journal-title":"N Engl J Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/2395-3977.168573","article-title":"Genetic Characteristics of Glioblastoma: Clinical Implications of Heterogeneity","volume":"1","author":"Tu","year":"2015","journal-title":"Cancer Transl Med"},{"key":"21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.18632\/oncotarget.969","article-title":"A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care","volume":"4","author":"Ketola","year":"2013","journal-title":"Oncotarget"},{"key":"22","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/bjc.2014.431","article-title":"In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells","volume":"111","author":"Aggrawal","year":"2014","journal-title":"Br J Cancer"},{"key":"23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-5876-12-13","article-title":"Novel anti- glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs","volume":"12","author":"Makale","year":"2014","journal-title":"J Transl Med"},{"key":"24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/1477-3163.75723","article-title":"Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers","volume":"10","author":"Scheper","year":"2011","journal-title":"J Carcinog"},{"key":"25","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Guenette","year":"2001","journal-title":"Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/JTO.0b013e31824c7d43","article-title":"Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners","volume":"7","author":"Tagawa","year":"2012","journal-title":"J Thorac Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.0910258107","article-title":"Dysregulation of the mevalonate pathway promotes transformation","volume":"107","author":"Penn","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Casey","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc3151","article-title":"Targeting protein prenylation for cancer therapy","volume":"11","author":"Sebti","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0092-8674(91)90460-G","article-title":"Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit","volume":"65","author":"Goldstein","year":"1991","journal-title":"Cell"},{"key":"31","doi-asserted-by":"crossref","first-page":"9746","DOI":"10.1021\/bi060295e","article-title":"Conversion of protein farnesyltransferase to a geranylgeranyltransferase","volume":"45","author":"Beese","year":"2006","journal-title":"Biochemistry"},{"key":"32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/1476-511X-10-243","article-title":"The mevalonate pathway in C. elegans","volume":"10","author":"Pilon","year":"2011","journal-title":"Lipids Health Dis"},{"key":"33","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1073\/pnas.0600316103","article-title":"Brain cholesterol turnover required for geranylgeraniol production and learning in mice","volume":"103","author":"Russell","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/jnc.12959","article-title":"Geranylgeranyl pyrophosphate is crucial for neuronal survival but has no special role in Purkinje cell degeneration in Niemann Pick type C1 disease","volume":"133","author":"Ohm","year":"2015","journal-title":"J Neurochem"},{"key":"35","first-page":"S80","article-title":"Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis","volume":"71","author":"O'Donnell","year":"1999","journal-title":"Kidney Int"},{"key":"36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/oxfordjournals.jbchem.a124695","article-title":"Geranylgeraniol is a potent inducer of apoptosis in tumor cells","volume":"117","author":"Nakaya","year":"1995","journal-title":"J Biochem"},{"key":"37","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.080517697","article-title":"Rab geranylgeranyl transferase alpha mutation in the gunmetal mouse reduces Rab prenylation and platelet synthesis","volume":"97","author":"Kingsmore","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/hmg\/11.6.697","article-title":"The gene for the muted (mu) mouse, a model for Hermansky-Pudlak syndrome, defines a novel protein which regulates vesicle trafficking","volume":"11","author":"Swank","year":"2002","journal-title":"Hum Mol Genet"},{"key":"39","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2174\/092986706777935078","article-title":"Inhibitors of protein: geranylgeranyl transferases","volume":"13","author":"Overhand","year":"2006","journal-title":"Curr Med Chem"},{"key":"40","doi-asserted-by":"crossref","first-page":"7384","DOI":"10.1021\/ja211305j","article-title":"Psoromic acid is a selective and covalent Rab-prenylation inhibitor targeting autoinhibited RabGGTase","volume":"134","author":"Goody","year":"2012","journal-title":"J Am Chem Soc"},{"key":"41","doi-asserted-by":"crossref","first-page":"8330","DOI":"10.1021\/jm300624s","article-title":"Development of selective, potent RabGGTase inhibitors","volume":"55","author":"Goody","year":"2012","journal-title":"J Med Chem"},{"key":"42","article-title":"The Rab GTPase family","volume":"2","author":"Olkkonen","year":"2001","journal-title":"Genome Biol"},{"key":"43","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1083\/jcb.152.4.795","article-title":"Rab27a regulates the peripheral distribution of melanosomes in melanocytes","volume":"152","author":"Seabra","year":"2001","journal-title":"J Cell Biol"},{"key":"44","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/1541-7786.MCR-07-0162","article-title":"Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II","volume":"6","author":"Shao","year":"2008","journal-title":"Mol Cancer Res"},{"key":"45","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3748\/wjg.v18.i15.1806","article-title":"Differential expression of Rab27A\/B correlates with clinical outcome in hepatocellular carcinoma","volume":"18","author":"Xiao","year":"2012","journal-title":"World J Gastroenterol"},{"key":"46","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12032-014-0372-2","article-title":"High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival","volume":"32","author":"Huang","year":"2015","journal-title":"Med Oncol"},{"key":"47","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1126\/science.279.5350.580","article-title":"Interaction of a Golgi- associated kinesin-like protein with Rab6","volume":"279","author":"Goud","year":"1998","journal-title":"Science"},{"key":"48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2015.03.004","article-title":"miR-5100 promotes tumor growth in lung cancer by targeting Rab6","volume":"362","author":"Liu","year":"2015","journal-title":"Cancer Lett"},{"key":"49","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/emboj\/21.6.1289","article-title":"Late endosome motility depends on lipids via the small GTPase Rab7","volume":"21","author":"Gruenberg","year":"2002","journal-title":"EMBO J"},{"key":"50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ccr.2014.04.030","article-title":"RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway","volume":"26","author":"Sanchez-Arevalo Lobo","year":"2014","journal-title":"Cancer Cell"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T03:52:03Z","timestamp":1749009123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,22]]},"references-count":50,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2016,9,6]]}},"alternative-id":["10773","27462771"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10773","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,22]]}}}